Skip to content

Clinical validation of a toothpaste containing 1% zinc citrate and 0.2% dipotassium glycyrrhizinate for inhibiting dental plaque and reducing gingivitis through fire clearing and gingival protection

Clinical validation of a toothpaste containing 1% zinc citrate and 0.2% dipotassium glycyrrhizinate for inhibiting dental plaque and reducing gingivitis through fire clearing and gingival protection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103416
Enrollment
Unknown
Registered
2025-05-29
Start date
2025-06-03
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis, periodontitis

Interventions

Experimental group:The subjects used the experimental product containing active ingredients ("1% zinc citrate, 0.2% dipotassium glycyrrhizinate") daily
Control Group:The subjects used a blank control without active ingredients ("1% zinc citrate, 0.2% dipotassium glycyrrhizinate") daily

Sponsors

The Third Affiliated Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Good overall health condition; 2) Both males and females are welcome, aged between 18 and 70 years old; 3) There are more than 20 natural teeth, no extensive restorations in the neck of the teeth, no untreated cavities in the teeth, gum recession not exceeding 3mm, and no severe periodontal disease (periodontal pocket depth exceeding 5mm, tooth looseness exceeding II) Degree); 4) Improved Quigley Hein plaque index >= 1.5; 5) Loe Silness gingivitis index >= 1.0, bleeding index >= 1.0 or (BOP% >=50%); 6) Subjects who have not used gum health products within the 4 weeks prior to the trial; 7) Sign the informed consent form, comply with the trial rules and requirements, and complete a 3.5-month clinical trial.

Exclusion criteria

Exclusion criteria: 1) Currently participating in clinical trials in other dental specialties; 2) Currently pregnant, breastfeeding, or having a pregnancy plan within the trial period; 3) Systemic diseases (such as immune system diseases, blood system diseases, malignant tumors, diabetes patients, etc.); 3) Teeth with extensive restoration, suspected pulpitis, dental caries, enamel cracking, and removable partial dentures as abutments; 4) Late stage periodontal disease or periodontal treatment (including periodontal surgery) received within the past year; 5) Take anti-inflammatory and antibacterial drugs during the trial period; 6) Subjects who have used gum health products within the 4 weeks prior to the trial. For example, mouthwash, dental irrigator, interdental brush, etc; 7) Those who wear full mouth or removable partial dentures or orthodontic appliances in their mouth; 8) More than 6 subjects with severe staining on the tooth surface during testing; 10) Allergies to any ingredients of the research product; 11) Use antibiotics within one month before the start of the experiment.

Design outcomes

Primary

MeasureTime frame
Decreased value of bleeding index (BI);Gingival Index (GI);Plaque Index (PI);

Countries

China

Contacts

Public ContactXiaomian Wu

The Third Affiliated Hospital of Southern Medical University

wuxiaomian898@163.com+86 158 2316 6266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026